Runs two business segments - Pharmaceuticals and Electronics - through group companies, generating consolidated revenue of Rs 202.27 crore in FY26. The Pharmaceuticals business is operated through Asence Pharma and the Electronics business through Systronics India, with Synbiotics as an additional group entity; both segments reported positive EBIT in FY26. Electronics was the faster-growing of the two in Q3 FY26, growing about 34% year-on-year while Pharmaceuticals stayed largely flat. On the cost side, raw materials are only 9.5% of revenue while employees absorb 16.1% and other operating expenses 19.2%, indicating limited direct commodity exposure. Depreciation of 1.9% and capex of 2.1% of revenue point to a low capital-intensity operating model. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals, Electronics. Diversified holding-style group with two operating segments - Pharmaceuticals and Electronics
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 197 | 170 | 174 | 196 | 202 |
| EBITDA (ex other income) | 10 | 9 | 6 | 1 | 11 |
| margin % | 5.0 | 5.0 | 3.6 | 0.6 | 5.4 |
| Owners' profit | 47 | 11 | 6 | 5 | 18 |
| EPS, as reported (₹) | 6.16 | 1.45 | 0.74 | 0.64 | 2.32 |
| ROE % · ROCE % | 39.4 · 39.6 | 8.5 · 12.2 | 4.1 · 8.9 | 3.5 · 5.7 | 11.2 · 12.1 |
| Debt / equity (x) | 0.21 | 0.31 | 0.33 | 0.35 | 0.33 |
| Cash from operations | 11 | 6 | 7 | (18) | 13 |
| Capex | (14) | (21) | (3) | (3) | (4) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 45 | 46 | 65 | 40 | 44 | 52 | 65 |
| Profit before tax | 1 | 2 | 3 | (2) | 8 | 0 | 4 | 6 |
| Net profit | 0 | 3 | 2 | (0) | 8 | (1) | 4 | 7 |
| EPS (₹) | 0.05 | 0.34 | 0.29 | 0.04 | 1.07 | 0.07 | 0.40 | 0.85 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 111 | 54.6 |
| Electronics | 92 | 45.4 |
| Total, before eliminations | 202 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 14 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 12 Aug 2026 · Q1 FY27 results: PAT drops 52% YoY to Rs 3.98 cr on margin pressure | results | high | — | — |
| 12 Aug 2026 · Q1 FY27 Results: Net Profit Falls 52 Percent YoY to Rs. 398 Lakhs | results | high | — | — |
| 6 Aug 2026 · No undisclosed info behind share price movement | compliance | minimal | — | — |
| 5 Aug 2026 · BSE seeks clarification on significant price movement from Ambalal Sarabhai Enterprises | regulatory legal | high | — | — |
| 5 Aug 2026 · Plant visit for shareholders rescheduled to 1 December 2026 | general | low | — | — |
| 5 Aug 2026 · Board Meeting on Aug 12, 2026 to Consider Q1 FY27 Results | results | low | — | — |
| 31 Jul 2026 · 48th AGM voting results: all 9 resolutions passed | board shareholder meetings | low | — | — |
| 30 Jul 2026 · 48th AGM held; 9 resolutions including director re-appointments tabled | board shareholder meetings | low | — | — |
| 13 Jul 2026 · Newspaper publication of 48th AGM notice submitted to BSE | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 17.2 | 28.9 | 47 of 169 | 73% |
| P/B | 2.0 | 3.3 | 50 of 163 | 70% |
| ROCE | 9.9 | 10.8 | 99 of 183 | 46% |
| ROE | 11.2 | 10.4 | 80 of 171 | 54% |
| Debt / Equity | 0.3 | 0.1 | 123 of 171 | 28% |
| EBITDA margin | 12.7 | 17.5 | 104 of 165 | 37% |
| Revenue growth | 1.0 | 16.3 | 122 of 161 | 24% |
| Profit growth | 2534.9 | 30.9 | 2 of 158 | 99% |
| Market cap | 316 | 839 | 104 of 182 | 43% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
